PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Management and Research"
DOI: 10.2147/cmar.s221001
Abstract: Abstract Advanced, recurrent and metastatic endometrial cancer (EC) has a dismal prognosis due to poor response rates to conventional treatments. In the era of precision medicine, the improved understanding of cancer genetics and molecular biology… read more here.
Keywords: status; cancer current; cancer; parp inhibitors ... See more keywords